Medicine · 2026
Prognostic and clinicopathological significance of CD133 in patients with hepatocellular carcinoma: A meta-analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kang Baoguo, Liang Dandan, Liu Dajie
Аннотация
BACKGROUND: This meta-analysis was conducted to investigate whether CD133 could be used as a biomarker to predict prognosis in hepatocellular carcinoma patients.
METHODS: We systematically retrieved relevant studies from these databases as of February 2026. Odds ratios and their 95% confidence intervals were used to estimate the association between CD133 expression and clinicopathological features. The associations between CD133 and survival outcomes, including overall survival (OS), disease-free survival, and recurrence-free survival, were estimated by hazard ratios and 95% confidence intervals.
RESULTS: A total of 25 publications were included, involving 3278 patients. CD133 was highly expressed in liver cancer tissues (P < .05). Also, CD133 expression was associated with tumor size, tumor node metastasis stage, and tumor differentiation (P < .05). CD133-positive expression had shorter OS, disease-free survival, and recurrence-free survival than those with CD133-negative expression (P < .05).
CONCLUSION: This meta-analysis suggests that CD133 is a potential biomarker for predicting poor survival in Asian hepatocellular carcinoma patients, especially for OS.
METHODS: We systematically retrieved relevant studies from these databases as of February 2026. Odds ratios and their 95% confidence intervals were used to estimate the association between CD133 expression and clinicopathological features. The associations between CD133 and survival outcomes, including overall survival (OS), disease-free survival, and recurrence-free survival, were estimated by hazard ratios and 95% confidence intervals.
RESULTS: A total of 25 publications were included, involving 3278 patients. CD133 was highly expressed in liver cancer tissues (P < .05). Also, CD133 expression was associated with tumor size, tumor node metastasis stage, and tumor differentiation (P < .05). CD133-positive expression had shorter OS, disease-free survival, and recurrence-free survival than those with CD133-negative expression (P < .05).
CONCLUSION: This meta-analysis suggests that CD133 is a potential biomarker for predicting poor survival in Asian hepatocellular carcinoma patients, especially for OS.